Large-scale purification of 90Sr from nuclear waste materials for production of 90Y, a therapeutic medical radioisotope

Applied Radiation and Isotopes

Volumn 59, Issue 1, 2003, Pages 35-41

  Wester, Dennis W ^a   Steele, Richard T ^a   Rinehart, Donald E ^a   DesChane, Jaquetta R ^a   Carson, Katharine J ^a   Rapko, Brian M ^a   Tenforde, Thomas S ^a,b  

^a PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

^b Natl Cncl Radiat Protect M   (United States)

Author keywords

90Sr purification; 90Y; Fission waste impurities; Medical isotopes

Indexed keywords

GRAVIMETRIC ANALYSIS; PRECIPITATION (CHEMICAL); PURIFICATION; RADIOACTIVE WASTES;

FISSION WASTE MATERIALS;

STRONTIUM;

ACTINIDE; CARBONIC ACID; CESIUM 137; STAINLESS STEEL; STRONTIUM 90; URANIUM; YTTRIUM 90; CESIUM; RADIOPHARMACEUTICAL AGENT; STRONTIUM; YTTRIUM;

ALKALINITY; ARTICLE; GRAVIMETRY; NUCLEAR WASTE; PRECIPITATION; PRESSURE; PRIORITY JOURNAL; PURIFICATION; RADIOCHEMISTRY; SOLID STATE; CHEMISTRY; ISOLATION AND PURIFICATION; RADIOACTIVE WASTE; SYNTHESIS;

CESIUM RADIOISOTOPES; PRECIPITATION; RADIOACTIVE WASTE; RADIOPHARMACEUTICALS; STRONTIUM RADIOISOTOPES; YTTRIUM RADIOISOTOPES;

EID: 0142026850     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8043(03)00151-9     Document Type: Article

References (17)

1. 90Y at Hanford. Radioact. Radiochem. 3:1992;22-25.
2. DeNardo S.J., Kroger L.A., DeNardo G.L. A new era for radiolabeled antibodies in cancer? Curr. Opin. Immunol. 11:1999;563-569.
3. Deshpande S.V., DeNardo S.J., Kukis D.L., Moi M.K., McCall M.J., DeNardo G.L., Meares C.F. Yttrium-90-labeled monoclonal antibody for therapy. labeling by a new macrocyclic bifunctional chelating agent J. Nucl. Med. 30:1989;473-479.
4. Frost, Sullivan, 1997. FFTF Medical Isotopes Market Study (2001-2020). Report No. PNNL-11774, Mountain View, CA.
5. Frost, Sullivan, 2000. US Radiopharmaceutical Markets. Report No. 5523-50, Mountain View, CA.
6. Grana C., Chinol M., Robertson C., Mazzetta C., Bartolomei M., De Cicco C., Fiorenza M., Gatti M., Caliceti P., Paganelli G. Pretargeted adjuvant radioimmunotherapy with Yttrium-90-biotin in malignant glioma patients. a pilot study Br. J. Cancer. 86:2002;207-212.
7. Heuft-Dorenbosch L.L.J., de Vet H.C.W., van der Linden S. Yttrium radiosynoviorthesis in the treatment of knee arthritis in rheumatoid arthritis. a systematic review Ann. Rheum. Dis. 59:2000;583-586.
8. Hosaka, T.Y., Sevigny, G.J., Schlender, M.H., 1996. High level liquid waste treatment process: reducing risk and capitalizing on high value isotopes. In: Proceedings of the Waste Management Spectrum '96, Seattle, WA, August 18-23, 1996. American Nuclear Society, Inc., La Grange Park, IL 60526, USA.
9. 90Y with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), a model for cancer radioimmunotherapy. J. Am. Chem. Soc. 121:1999;6142-6151.
10. Kat S., Kutz R., Elbracht T., Weseloh G., Kuwert T. Radiosynovectomy in pigmented villonodular synovitis. Nuklearmed. -Nucl. Med. 39:2000;209-213.
11. Mirzadeh S., Brechbiel M.W., Atcher R.W., Gansow O.A. Radiometal labeling of immunoproteins. covalent linkage of 2-(4-isothiocyanatobenzyl) diethylenetriaminepentaacetic acid ligands to immunoglobulin Bioconjugate Chem. 1:1990;59-65.
12. Shikani A.H., Richtsmeier W.J., Klein J.L., Kopher K.A. Radiolabeled antibody therapy for squamous-cell carcinoma of the head and neck. Arch. Otolaryngol. Head Neck Surg. 118:1992;521-525.
13. Vriesendorp H.M., Morton J.D., Quadri S.M. Review of five consecutive studies of radiolabeled immunoglobulin therapy in Hodgkin's disease. Cancer Res. 55(Suppl.):1995;5888S-5892S.
14. Vriesendorp H.M., Quadri S.M., Wyllie C.T., Lai J., Borchardt P.E., Harris L., Wucher R., Askew E., Schweichler L. Fractionated radiolabeled antiferritin therapy for patients with recurrent Hodgkin's disease. Clin. Cancer Res. 5(Suppl. S):1999;3324S-3329S.
15. Waksman R., Bhargava B., White L., Chan R.D., Mehran R., Lansky A.J., Mintz G.S., Satler L.F., Pichard A.D., Leon M.B., Kent K.K. Intracoronary beta-radiation therapy inhibits recurrence of in-stent restenosis. Circulation. 101:2000;1895-1898.
16. Wiseman G.A., Leigh B., Erwin W.D., Lamonica D., Kornmehl E., Spies S.M., Silverman D.H.S., Witzig T.E., Sparks R.B., White C.A. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer. 94:2002;1349-1357.
17. Witzig R.E. Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma. Cancer Chemother. Pharmacol. 48:2001;591-595.